(Q35145012)

6 August 2017

1 reference

title

Review article: medical treatment of mild to moderately active Crohn's disease (English)

1 reference

6 August 2017

0 references

Löfberg R

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Alimentary Pharmacology & Therapeutics

6 August 2017

published in

1 reference

6 August 2017

volume

17 Suppl 2

1 reference

6 August 2017

page(s)

18-22

1 reference

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.22.X

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.22.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.22.X

Management of perianal Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.22.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.22.X

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.22.X

10.1046/J.1365-2036.17.S2.22.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference